BEST PRACTICE FOR A COMPLIANT INSTITUTIONAL BIOSAFETY COMMITTEE

摘要

In the US, an Institutional Biosafety Committee (IBC) is required for institutions that receive federal funding from the US National Institutes of Health (NIH) and/or are subject to a local ordinance that applies to work with recombinant or synthetic nucleic acid molecules. The institution must adhere to the requirements of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The IBC is the cornerstone of the Biosafety Management System. Each IBC is unique yet there are best practices that will help every IBC function optimally to meet better its goal of protecting workers and the community. Whether the work covered under the NIH Guidelines pertains to research, clinical or manufacturing efforts, the IBC is an important part of the overall Biosafety Programme. The following points cover some major areas that should be considered.